earAuris Medical Holding AG (NASDAQ: EARS) is having an incredibly strong start to the trading session this morning, and for good reason. The company is expected to provide a clinical update tomorrow morning, and investors are excited for what they’re going to learn. Today, we’ll talk about:
- The coming clinical update;
- what we’re seeing from EARS stock as a result; and
- what we’ll be watching for ahead.
EARS Heads Up On Coming Clinical Update
As mentioned above, Auris Medical is having an incredibly strong start to the trading session this morning following up on the strong gains seen on the stock yesterday. The gains are coming for good reason too. A few days ago, the company announced that it would be providing a clinical update tomorrow, October 17, 2018.
In the press released announcement, EARS said that it would be holding a conference call to provide an update on its intranasal betahistine program. In the update, the company plans on providing key results from the second Phase 1 clinical trial of the treatment.
The conference will be held tomorrow at 8:00 am EST. If you would like to be a party to the conference, simply call 1-877-407-0312 and enter the passcode 1364198. Of course, there will be a replay of the conference available on the EARS investor relations website.
What We’re Seeing From The Stock
As investors, one of the first lessons that we learn is that it’s important to keep close tabs on the news and track catalystic events. After all, this is ultimately what causes the majority of movement in the market. So, it comes as no surprise that with Auris Medical providing a clinical update tomorrow, investors are excited today and pushing the stock toward the top. Of course, our partners at Trade Ideas were the first to alert us to the gains. At the moment (10:16), EARS is trading at $1.79 per share after a gain of $0.41 per share or 29.71% thus far today.
Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!
What We’ll Be Watching For Ahead
Moving forward, the CNA Finance team will continue to keep a close eye on EARS. In particular, we’re interested in following the story surrounding the company’s coming clinical update. Nonetheless, we’ll continue to keep a close eye on the news and bring it to you as it breaks!
Never Miss The News Again
Do you want real-time, actionable news delivered to your inbox? Join the CNA Finance mailing list below!